



# Impact of Hormonal Contraceptives on the Mental Health of Reproductive Age Women

GENERAL  
EDITION  
60TH ANNIVERSARY

Duru Vivian O.<sup>1</sup>

<sup>1</sup> 500 level Medical Student, University of Ibadan, Ibadan (at time of writing)

## ABSTRACT

Hormonal contraceptives, which include oral pills, injectables, implants, and intrauterine devices, have revolutionized reproductive health by offering effective family planning options and management of gynecological conditions. However, their impact on women's mental health remains a subject of debate. This review explores the relationship between hormonal contraceptive use and mental health outcomes, with a focus on depression, anxiety, and mood disorders among women of reproductive age. A comprehensive examination of population-based studies, systematic reviews, and clinical trials reveals mixed findings. While some studies suggest a potential link between hormonal contraceptive use, particularly combination pills, and an increased risk of depression and mood disturbances, others report no significant association. The biological mechanisms underlying these effects may involve alterations in neurotransmitter regulation, hormone receptor sensitivity, and the disruption of estrogen and progesterone levels, which are key to mood stabilization. Special attention is given to vulnerable groups, such as adolescents and women with a prior history of mental health disorders, who may be at higher risk of experiencing adverse mood effects. The variability in study outcomes underscores the need for personalized contraceptive counseling that includes mental health screening and monitoring. By facilitating informed decision-making, healthcare providers can better support women in choosing the most suitable contraceptive method while safeguarding their mental well-being. Future research is needed to clarify the long-term mental health impacts of hormonal contraceptives and to identify those most at risk of negative outcomes.

Correspondence to:

veveduru@gmail.com,

+234 816 061 3662

**Keywords:**

*Hormonal contraceptives, Mental health, Women, Depression, Mood disorders.*

DOI: <https://dx.doi.org/10.4314/dokita.v4i1.4>

## INTRODUCTION

Hormonal contraceptives have revolutionized family planning and women's health by providing effective methods for contraception and managing various gynecological conditions like Polycystic Ovarian Syndrome (PCOS), endometriosis, and menstrual disorders. These contraceptives encompass a wide range of options, including combination pills, progestin-only methods, patches, and intrauterine devices (IUDs)<sup>1</sup>. They work by modulating the hormonal environment, primarily by suppressing ovulation and altering hormonal levels to prevent pregnancy. The widespread use of hormonal contraceptives underscores their importance in modern healthcare,

with millions of women relying on them for contraception and menstrual cycle regulation<sup>2</sup>. However, beyond their primary contraceptive effects, there is a growing concern about the potential impact of hormonal contraceptives on mental health.

This emerging area has sparked considerable interest and debate among healthcare providers, researchers, and women themselves. Understanding the relationship between hormonal contraceptives and mental health outcomes is crucial for several reasons. Mental health is a fundamental aspect of overall well-being, and any intervention that affects mental health warrants careful consideration<sup>3</sup>. Women's mental health can influence various aspects of their lives, including relationships,

work, and overall quality of life. Therefore, assessing the impact of hormonal contraceptives on mental health is essential for providing comprehensive healthcare to women<sup>4</sup>. The potential association between hormonal contraceptives and mental health has significant implications for contraceptive decision-making and patient care. Women deserve accurate information about the potential benefits and risks of hormonal contraceptives to make informed choices about their reproductive health<sup>5</sup>.

## MECHANISMS OF ACTION

Hormonal contraceptives encompass various types, each with its unique composition and mechanism of action. Combination pills, the most commonly prescribed form of hormonal contraception, contain synthetic versions of estrogen and progestin hormones. These hormones work together to inhibit ovulation by suppressing the release of gonadotropins from the pituitary gland, thereby preventing follicular development and ovulation<sup>6</sup>. Progestin-only methods, such as progestin-only pills, injectables, implants, and hormonal IUDs, primarily exert their contraceptive effects by thickening cervical mucus, inhibiting sperm penetration, and altering the endometrial lining to prevent implantation of a fertilized egg<sup>7</sup>. Hormonal contraceptives can influence neurotransmitter levels and hormonal balance, potentially impacting mood and mental health<sup>8</sup>.

Estrogen and progesterone receptors are widely distributed throughout the brain, including areas involved in mood regulation, such as the limbic system and prefrontal cortex. By altering hormonal levels, hormonal contraceptives may modulate neurotransmitter systems, including serotonin, dopamine, and gamma-aminobutyric acid (GABA), which play key roles in mood regulation and emotional processing<sup>9</sup>. Several potential pathways have been proposed to link hormonal contraceptives to mental health outcomes. One proposed mechanism involves alterations in neurotransmitter levels and receptor sensitivity, leading to mood disturbances and affective symptoms<sup>10</sup>. Another hypothesis suggests that hormonal contraceptives may disrupt the delicate balance of sex hormones, including estrogen and progesterone, which are known to modulate mood and behavior<sup>11</sup>.

## REVIEW OF RESEARCH FINDINGS

Numerous studies have investigated the association between hormonal contraceptives and mental health outcomes in women. For example, Skovlund et al. conducted a large-scale population-based cohort study to examine the association between hormonal contraceptive use and the subsequent initiation of antidepressant therapy. They found a statistically significant association between the use of hormonal contraceptives, particularly combination pills, and the initiation of antidepressant therapy, suggesting a potential link between hormonal contraceptive use and depression risk<sup>12</sup>. Other studies have focused on specific mental health outcomes, such as anxiety and mood disorders, in relation to hormonal contraceptive use<sup>13</sup>.

Several meta-analyses and systematic reviews have been conducted to synthesize the existing evidence on the relationship between hormonal contraceptives and mental health outcomes. For example, a meta-analysis by Eyre et al. examined the association between hormonal contraceptive use and depressive symptoms in adolescents and young adult women. They found a modest association between hormonal contraceptive use and increased depressive symptoms, particularly among adolescents, highlighting the importance of considering age-related differences in susceptibility to mental health effects<sup>14</sup>. Similarly, a systematic review by Lopez et al. evaluated the impact of hormonal contraceptive use on mood and quality of life in women with premenstrual dysphoric disorder (PMDD). They concluded that hormonal contraceptives, particularly those containing drospirenone, may alleviate symptoms of PMDD and improve overall quality of life in affected women<sup>15</sup>.

Despite the wealth of research on this topic, there is considerable variability in study results, with some studies reporting significant associations between hormonal contraceptives and mental health outcomes, while others find no such associations<sup>16</sup>. This variability can be attributed to several factors, including differences in study design, population characteristics, and methodological limitations. For instance, studies vary in terms of their study populations, with some focusing on specific demographic groups, such as adolescents or women with pre-existing mental health conditions, while others include broader populations<sup>17</sup>. Additionally, differences in hormonal contraceptive formulations, dosages, and routes of administration may contribute to variability in study results. Methodological limitations, such as retrospective

study designs, reliance on self-reported outcomes, and inadequate adjustment for confounding factors, may also influence the validity and generalizability of findings<sup>18</sup>.

## RISK FACTORS

Several potential risk factors and vulnerable populations have been identified in relation to the impact of hormonal contraceptives on mood and mental health outcomes. Women with a history of mood disorders, such as depression or anxiety, may be at increased risk of experiencing adverse mental health effects while using hormonal contraceptives<sup>19</sup>. Additionally, psychosocial stressors, such as relationship conflicts or life transitions, may exacerbate the impact of hormonal contraceptives on mood and mental health. Individual differences in hormonal response and susceptibility to mental health effects play a significant role in determining the impact of hormonal contraceptives on women's mental health<sup>20</sup>.

Genetic factors, hormonal fluctuations, and neurobiological differences may contribute to variability in individual responses to hormonal contraceptives. For example, variations in estrogen and progesterone receptor sensitivity may influence how women respond to hormonal contraceptive formulations, with some individuals experiencing mood improvements while others may develop adverse mood effects<sup>21</sup>. Age and hormonal contraceptive formulation may also influence mental health outcomes, as younger women (under 20) are more susceptible to negative mental health effects from hormonal contraceptives, especially with high-dose estrogen and progestin-only pills, while older women (over 40) may experience fewer mental health issues with low-dose estrogen and progestin-only implants<sup>22</sup>.

## CLINICAL IMPLICATIONS AND RECOMMENDATIONS

Healthcare providers play a crucial role in providing comprehensive contraceptive counseling to women, which includes discussing potential mental health effects associated with hormonal contraceptives. Incorporating routine mental health screening into contraceptive care can help identify women at risk of experiencing adverse mental health effects related to hormonal contraceptives<sup>23</sup>. Recognizing the heterogeneity in women's responses to hormonal contraceptives underscores the importance of individualized contraceptive care. Educating women about the potential mental health effects of hormonal contraceptives empowers them to make informed decisions about their reproductive health<sup>24</sup>.

## CONCLUSION

In light of the multifaceted nature of the relationship between hormonal contraceptives and mental health, it becomes evident that there is no one-size-fits-all approach. Moving forward, it is imperative to prioritize further research initiatives that delve deeper into the underlying mechanisms and long-term effects of hormonal contraceptive use<sup>25</sup>. Furthermore, healthcare providers must remain vigilant in assessing and addressing mental health concerns in women using hormonal contraceptives. In conclusion, by embracing a holistic approach that integrates evidence-based research findings with patient-centered care, we can empower women to make informed decisions about their reproductive health while safeguarding their mental well-being.

## REFERENCES

- Hall, K. S., Steinberg, J. R., Cwiak, C. A., Allen, R. H., & Marcus, S. M. (2016). Contraception and mental health: A commentary on the evidence and principles for practice. *American Journal of Obstetrics and Gynecology*, 215(6), 1-5.
- Skovlund, C. W., Mørch, L. S., Kessing, L. V., & Lidegaard, Ø. (2016). Association of hormonal contraception with depression. *JAMA Psychiatry*, 73(11), 1154-1162.
- Thalia Robakis, Katherine E Williams, Lexi Nutkiewicz, Natalie L Rasgon). Hormonal contraception and mood: Review of the literature and implications for future research. *Current psychiatry reports* 21, 1-9, 2019
- Mørch, L. S., Skovlund, C. W., Hannaford, P. C., Iversen, L., Fielding, S., Lidegaard, Ø., & Mikkelsen, E. M. (2017). Contemporary hormonal contraception and the risk of breast cancer. *New England Journal of Medicine*, 377(23), 2228-2239.
- Eyre, H. A., Air, T., Pradhan, A., Johnston, J., Lavretsky, H., Stuart, M. J., ... & Baune, B. T. (2019). A meta-analysis of chemokines in major depression. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 91, 94-104.
- Skovlund, C. W., Mørch, L. S., Kessing, L. V., & Lidegaard, Ø. (2016). Association of hormonal contraception with depression. *JAMA Psychiatry*, 73(11), 1154-1162.
- Gingnell, M., Engman, J., Frick, A., Moby, L., Wikstrom, J., Fredrikson, M., ... & Sundstrom-Poromaa, I. (2013). Oral contraceptive use changes brain activity and mood in women with previous negative affect on the pill--a

- double-blinded, placebo-controlled randomized trial of a levonorgestrel-containing combined oral contraceptive. *Psychoneuroendocrinology*, 38(7), 1133-1144.
8. Wiegratz, I., & Kuhl, H. (2004). Metabolic and clinical effects of progestogens. *European Journal of Contraception & Reproductive Health Care*, 9(2), 69-79.
  9. Desai HD, Jann MW. Major depression in women: a review of the literature. *J Am Pharm Assoc (Wash)*. 2000;40(4):525-537.
  10. Piccinelli M, Wilkinson G. Gender differences in depression: critical review. *Br J Psychiatry*. 2000;
  11. Noble RE. Depression in women. *Metabolism*. 2005;54(5) (suppl 1):49-52.
  12. Skovlund, C. W., Mørch, L. S., Kessing, L. V., Lange, T., & Lidegaard, Ø. (2018). Association of hormonal contraception with suicide attempts and suicides. *American Journal of Psychiatry*, 175(4), 336-342.
  13. Hammarstrom A, Lenti A, Danielsson U, Bengs C, Johansson EE. Gender-related explanatory models articles. *Public Health*. 2009;123(10):689-693
  14. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey, I: lifetime prevalence, chronicity and recurrence. *J Affect Disord*. 1993;29(2-3):85-96.
  15. Lopez, L. M., Grey, T. W., Chen, M., & Tolley, E. E. (2013). Hormonal contraceptives for contraception in overweight or obese women. *Cochrane Database of Systematic Reviews*, 4(4), CD008452.
  16. Wesselhoeft R, Pedersen CB, Mortensen PB, Mors O, Bilenberg N. Gender-age interaction in incidence rates of childhood emotional disorders. *Psychol Med*. 2015;45(4):829-839.
  17. Joffe H, Cohen LS. Estrogen, serotonin, and the therapeutic bridge?
  18. Schmidt PJ, Nieman LK, Danaceau MA, Adams LR, Kubinow UK. Utererential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. *N Engl J Med*. 2001;330(14):210.
  19. McEwen BS. Invited review: estrogens effects on the brain: multiple sites and molecular mechanisms. *J Appl Physiol* (1985). 2001;91(6): 2785-2801.
  20. Hall KS, White KO, Rickert VI, Reame N, Westhoff C. Influence of depressed mood and psychological stress symptoms on perceived oral contraceptive side effects and discontinuation in young minority women. *Contraception*. 2012;86(5):
  21. Inoue K, Barratt A, Richters J. Does research into contraceptive method address women's own reasons? a critical review. *J Fam Plann Reprod Health Care*. 2015;41(4):292-299.
  22. Toffoletto S, Lanzenberger R, Gingnell M, Sundström-Poromaa I, Comasco E. Emotional and cognitive functional imaging of estrogen and progesterone effects in the female human brain: a systematic review. *Psychoneuroendocrinology*. 2014;50:28-52.
  23. Holst J, Backstrom T, Hammarback S, von Schoultz B. Progesterone addition during estrogen replacement therapy: symptoms and mood. *Maturitas*. 1989;11(1):13-20
  24. Sherwin BB. The impact of different doses of behavior in postmenopausal women. *J Clin Endocrinol Metab*. 1991;72(2):336-343.
  25. Graham CA, Ramos R, Bancroft J, Maglaya C, Farley TMM. The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind, placebo-controlled, two-center study of combined and progestogen only methods. *Contraception*. 1995;52(6):363-369.